Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
The investors in Marksans Pharma Limited's (NSE:MARKSANS) will be rubbing their hands together with glee today, after the share price leapt 22% to ₹333 in the week following its first-quarter results. The result was positive overall - although revenues of ₹8.4b were in line with what the analysts predicted, Marksans Pharma surprised by delivering a statutory profit of ₹3.47 per share, modestly greater than expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Following the latest results, Marksans Pharma's three analysts are now forecasting revenues of ₹35.7b in 2027. This would be a decent 13% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to swell 10% to ₹12.55. In the lead-up to this report, the analysts had been modelling revenues of ₹34.9b and earnings per share (EPS) of ₹11.85 in 2027. So there seems to have been a moderate uplift in sentiment following the latest results, given the upgrades to both revenue and earnings per share forecasts for next year.
View our latest analysis for Marksans Pharma
With these upgrades, we're not surprised to see that the analysts have lifted their price target 22% to ₹324per share. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Marksans Pharma analyst has a price target of ₹385 per share, while the most pessimistic values it at ₹210. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Marksans Pharma's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Marksans Pharma'shistorical trends, as the 17% annualised revenue growth to the end of 2027 is roughly in line with the 17% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 12% annually. So although Marksans Pharma is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Marksans Pharma's earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Marksans Pharma going out to 2029, and you can see them free on our platform here.
You still need to take note of risks, for example - Marksans Pharma has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.